Brolucizumab ELISA Kit (GXEL00131)

Brolucizumab ELISA Kit

The Brolucizumab ELISA Kit (SKU: GXEL00131) is a quantitative sandwich ELISA designed for the accurate quantitative detection of Brolucizumab across Plasma, Serum. With a working range of 1.5625 ng/mL — 100 ng/mL, the kit combines a simple protocol with dependable colorimetric read-out for confident quantification.

Brolucizumab is the first and only single-chain variable fragment (scFv) targeting vascular endothelial growth factor (VEGF)-A. It has a smaller molecular weight (26 kDa). The mAb is undergoing evaluation as a treatment for neovascular age-related macular degeneration (nAMD). In June 2017, Novartis announced that the primary efficacy endpoint of non-inferiority to aflibercept (EYLEA®) in mean change in best-corrected visual acuity from baseline to week 48 was met in the Phase 3 HAWK (NCT02307682) and HARRIER (NCT02434328) studies, which included more than 1, 800 patients. The two studies compared the efficacy and safety of intravitreal injections of 6 mg brolucizumab or 3 mg brolucizumab (HAWK study only) versus 2 mg aflibercept in patients with nAMD. Of patients receiving 6 mg brolucizumab, 57% (HAWK) and 52% (HARRIER) were maintained exclusively on an every 12 week dosing interval immediately following the loading phase and continuing through week 48.54 Key secondary endpoints were also met. Novartis is developing a competitive, low cost of goods formulation, and expects to complete the PK study with antibody derived from the final manufacturing process to enable filing in 2018.

Backed by Assay Genie quality control and technical support, this Brolucizumab ELISA Kit is an ideal tool for laboratories studying Brolucizumab. Order the Brolucizumab ELISA Kit from Assay Genie for dependable performance.